Analytes/procedures in bold
type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
- This proficiency challenge is for laboratories performing gene panels, exome sequencing, and whole genome sequencing to detect germline variants associated with inherited forms of cancer.
- Participants will be asked to identify variants in the following genes: BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, and PMS2.
- Three 80.0-μL purified extracted DNA specimens (50 ng/μL)
Shipment A: February 26
Shipment B: August 20